|
About Company (This is info from the company website, not our
comments. Look below for our rating.) |
The history of Legacy goes back to the 1980’s when two of the largest
and most respected companies in America, Con Agra and Dupont, formed a
joint venture to develop products that could benefit animal and human
health. They quickly realized that one of the keys
to maintaining a healthy body was a healthy immune system.
The AIDS epidemic that captured the world’s attention at that
time, gave a sharp warning as to what happened to the human body when
its immune system was compromised.
Their joint venture, Dupont ConAgra Visions, began by studying the
most natural way of strengthening the immune system, namely when a
human or animal mother passed on her own natural antibodies to her
newborn. Their scientists worked with both cows and chickens to
determine whether human antibodies placed in the mother cow or hen
could be successfully passed to their offspring.
After years of work, a scientific team, led by Dr. Hellen Greenblatt,
who is now Legacy’s Chief Science Officer, proved that this transfer
process was possible, and that the passage of antibodies from the
hen’s egg was much more efficient than from a cow’s milk.
So they focused on the hen-to-chick transfer and began to
acquire all of the existing technology and patents for the processes
known as “hyperimmune egg” technology.
By the mid 90’s, Dr. Greenblatt and her team had perfected the
human applications and were verifying them in clinical trials. In
1995, market research was conducted to determine how to best bring the
product to market and two ways were isolated – either the
pharmaceutical or the dietary supplement channel. It was estimated
that an additional $150 million and 10 years of research and
development would be needed for the pharmaceutical route, so the
decision was made to market the hyperimmune egg technology as a
dietary supplement. Once that decision was made,
DuPont and ConAgra determined that this did not fit with their
companies’ missions, so they spun off their joint venture as well as
some other research companies to create a new, independent
biotechnology group of companies called DCV, Inc., in which neither
DuPont nor ConAgra had ownership. DCV’s first
mission was to get the hyperimmune egg product to market, and thus was
immune26® born.
Because immune26® is a completely natural whole food, the direct
sales channel was chosen because it provided the quickest and most
economical route into the marketplace. The
traditional wholesale and retail channels were eliminated when it was
realized that the true benefits the product brings to consumers cannot
be effectively explained in an advertisement, while the direct sales
route allows an individual to tell that story directly to another
person. So, Legacy for Life was created in October
of 1998 to market and distribute the hyperimmune egg technology
through the direct sales channel. Hens were
exposed to inactive pathogens, thus developing special immune factors,
which were then passed into their eggs. With a
unique patented process, the eggs were spray freeze-dried into a
powder. Because this powder contained 26 different
types of antibodies, the product was named “immune26”.
Through effective sales and marketing, Legacy grew to $30 million
by 2002. However, Legacy’s continued growth was
being inhibited by its owners need to support other companies in their
portfolio. So in October of 2002, a private group
of investors, Legacy Investment Group, LLC, bought the majority
control of Legacy and obtained the exclusive worldwide rights to the
hyperimmune egg technology.
During the first five years, growth at Legacy was primarily fuelled
by extending the immune26 product line from powder, to drink mix, to
capsules, to chewable tablets. Then at the start of 2004 a new
state-of-the-art weight management program was introduced around a
proprietary meal replacement shake that incorporated immune26, as well
as a number of effective ingredients that reflected the latest
scientific findings on low carbs and high fiber.
The program called Legacy BALANCE for Life was immediately successful
and the first production run was sold out in a week!
At the July 2004 Conference, the BALANCE Plan was rounded out with
an Omega-3 product, EICO-BALANCETM, a CLA product that enhanced the
program’s weight loss capabilities, and an exciting exercise program.
In addition, we added an anti-aging super anti-oxidant with essential
phytonutrients, vitamins and minerals called Legacy ESSENTIALS for
Life. However, we didn’t restrict our product
expansion to the normal dietary supplement marketplace.
It is our belief that if you want to help the largest number of
people you have to compete in large, expanding marketplaces. So, in
addition to the new products previously mentioned, we entered the $34
billion pet care market with Legacy COMPANION for Life, a line of
immune26-based dietary supplements for cats and dogs. At the same time
we announced that in early 2005 we would enter the $50 billion
personal care marketplace with or own unique skin care line.
Today, Legacy is a successful, profitable distribution company of
30,000 Distributors in four countries servicing customers in over 35
nations with a well-conceived balanced product line that meets the
needs of an increasingly aware population in one
of the fastest growing industries of all time – the health and
wellness industry. This industry has been reliably
forecasted to reach one trillion dollars by the year 2010.
|
